11:00 AM EDT, 07/15/2025 (MT Newswires) -- BioXcel Therapeutics ( BTAI ) said Tuesday in a regulatory filing that the US Patent and Trademark Office allowed a new patent related to a single dose of up to 120 micrograms of dexmedetomidine, delivered as an oromucosal formulation.

The dose is for treating acute agitation in patients with schizophrenia or bipolar disorder who meet specific heart safety criteria, the company said.

The patent aligns with the approved dosing of Igalmi for patients with limited QT prolongation and, once formally issued, will be listed in the Food and Drug Administration's Orange Book as the 14th patent for Igalmi, the company said.

The patent is set to expire on January 12, 2043, pending any patent term adjustments, BioXcel said.

Shares of BioXcel Therapeutics ( BTAI ) were up nearly 9% in recent trading activity.

Price: 2.20, Change: +0.18, Percent Change: +8.91